McDermott Advises Orakl Oncology on Fundraising - McDermott Will & Emery

McDermott Advises Orakl Oncology on Fundraising

Overview


McDermott Will & Emery has advised Orakl Oncology, a precision oncology start-up, on its fundraising to develop its techbio platform that integrates best-in-class biology with real-world patient data at scale to accurately model tumors and accelerate oncology drug development

McDermott team that advised Orakl Oncology comprised:

  • Anthony Paronneau, Anne-France Moreau, partners, and Ludivine Rabreau, associate

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.